Tecvayli Monotherapy Application Submitted to the EMA for Relapsed/refractory Multiple Myeloma After at Least One Prior Therapy
March 11, 2026
March 11, 2026
RARITAN, New Jersey, March 11 -- Johnson and Johnson Innovative Medicine issued the following news release on March 10, 2026:
* * *
TECVAYLI(R)/ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy/1
Teclistamab monotherapy delivere . . .
* * *
TECVAYLI(R)/ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy/1
Teclistamab monotherapy delivere . . .